Updated recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer

Summary Prostate cancer is the most prevalent male urogenital malignancy. Approximately 30% of patients with prostate cancer will develop advanced disease. Androgen deprivation therapy achieves disease control in about 90% of these patients, but the majority of them will eventually develop progressi...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Critical reviews in oncology/hematology 2015-11, Vol.96 (2), p.308-318
Hauptverfasser:	Climent, Miguel Ángel, León-Mateos, Luis, González del Alba, Aránzazu, Pérez-Valderrama, Begoña, Méndez-Vidal, Mª José, Mellado, Begoña, Arranz, José Ángel, Sánchez-Hernández, Alfredo, Cassinello, Javier, Olmos, David, Carles, Joan
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Asymptomatic Castration-resistant prostate carcinoma Chemotherapy Hematology, Oncology and Palliative Medicine Hormonal therapies Humans Male Prostatic Neoplasms, Castration-Resistant - therapy Recommendations Symptomatic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!